PDA (Parental Drug Association) has selected ValGenesis - Validation Lifecycle Management System (VLMS) as a New Innovative Technology and announced during the Plenary session at PDA Annual meeting held at Chicago during April – 05
Keeping up with the latest manufacturing and control technologies are a critical responsibility of any manufacturer in the pharmaceuticals and biopharmaceuticals industries.
Over the last several years, health authorities in the United States and Europe have turned their attention to the apparent stagnation in manufacturing and control technologies used throughout the industries. They also have taken a hard look at their own regulatory requirements to identify necessary reforms to accommodate a new ‘innovation revolution’ within the industries.
To help companies operating in the regulated space, PDA has launched the New Innovative Technologies Exhibition (NITE) program in 2004 for the Annual meeting. For year 2005, PDA has selected two exciting and state-of-the-art of the art new technologies which impacts the community, ValGenesis was selected as one of the new technologies to automate the Corporate Validation Lifecycle. This selection process was fully vetted through the NITE selection process, which involves two peer-review systems – the NITE peer-review board and PDA Interest Groups.